Sagimet Biosciences, Inc. (SGMT)
9.42
+0.30
(+3.29%)
USD |
NASDAQ |
Nov 06, 10:28
Sagimet Biosciences Enterprise Value : 325.27M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 325.27M |
| November 04, 2026 | 379.02M |
| November 03, 2026 | 376.55M |
| November 02, 2026 | 360.49M |
| October 30, 2026 | 374.70M |
| October 29, 2026 | 406.21M |
| October 28, 2026 | 425.36M |
| October 27, 2026 | 405.59M |
| October 26, 2026 | 352.46M |
| October 23, 2026 | 353.69M |
| October 22, 2026 | 376.55M |
| October 21, 2026 | 379.02M |
| October 20, 2026 | 363.58M |
| October 19, 2026 | 309.21M |
| October 16, 2026 | 257.31M |
| October 15, 2026 | 266.58M |
| October 14, 2026 | 227.96M |
| October 13, 2026 | 254.84M |
| October 12, 2026 | 305.50M |
| October 09, 2026 | 313.53M |
| October 08, 2026 | 312.92M |
| October 07, 2026 | 310.44M |
| October 06, 2026 | 303.03M |
| October 05, 2026 | 319.71M |
| October 02, 2026 | 326.51M |
| Date | Value |
|---|---|
| October 01, 2026 | 340.72M |
| September 30, 2026 | 372.23M |
| September 29, 2026 | 338.25M |
| September 28, 2026 | 375.93M |
| September 25, 2026 | 332.69M |
| September 24, 2026 | 324.65M |
| September 23, 2026 | 405.59M |
| September 22, 2026 | 446.98M |
| September 21, 2026 | 429.07M |
| September 18, 2026 | 446.98M |
| September 17, 2026 | 451.93M |
| September 16, 2026 | 408.06M |
| September 15, 2026 | 408.06M |
| September 14, 2026 | 434.01M |
| September 11, 2026 | 434.01M |
| September 10, 2026 | 445.13M |
| September 09, 2026 | 432.77M |
| September 08, 2026 | 423.51M |
| September 04, 2026 | 437.72M |
| September 03, 2026 | 436.48M |
| September 02, 2026 | 440.81M |
| September 01, 2026 | 410.53M |
| August 31, 2026 | 395.70M |
| August 28, 2026 | 413.62M |
| August 27, 2026 | 425.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vanda Pharmaceuticals, Inc. | 98.56M |
| IDEAYA Biosciences, Inc. | 2.153B |
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.95M |
| Total Expenses (Quarterly) | 13.95M |
| EPS Diluted (Quarterly) | -0.2627 |
| Earnings Yield | -13.61% |
| Normalized Earnings Yield | -13.61 |